Skip to content
  • Clinical Evidence
  • PAD
    • PAD
    • DETOUR System
    • DETOUR System Evidence
    • DETOUR System Resources
    • DETOUR System Reimbursement
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
  • Procedural Training
  • For Patients
  • About Us
    • About Us
    • News
    • The Team
    • Careers
    • Contact Us
  • Clinical Evidence
  • PAD
    • PAD
    • DETOUR System
    • DETOUR System Evidence
    • DETOUR System Resources
    • DETOUR System Reimbursement
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
  • Procedural Training
  • For Patients
  • About Us
    • About Us
    • News
    • The Team
    • Careers
    • Contact Us
Back to News
  • November 16, 2016

Endologix Provides Update on Nellix PMA Process

PrevPreviousEndologix Appoints Matthew Thompson, M.D., as Chief Medical Officer
NextPositive Five-Year Results from the Global Ovation® Pivotal Trial Presented at 2016 VEITH SymposiumNext
FIND IFU HERE
Youtube Linkedin Twitter

Compliance

Privacy Policy

Safety Information

Anti-Trafficking/Modern Slavery

Cookie Policy

Terms & Conditions

Patents

© 2025 Endologix LLC. All rights reserved.

Endologix® products and associated components are not available in all countries or regions. Please contact your Endologix representative for details regarding product availability. Prior to use, refer to the “Instructions for Use” for complete and specificindications, contraindications, all warnings and precautions. Rx only.